MOUNTAIN VIEW, Calif., Oct. 10, 2012 /PRNewswire via COMTEX/ — The treatment beyond standard of care for ankylosing spondylitis (AS) pharmacotherapeutics currently consists of a single drug class – tumor necrosis factor (TNF) inhibitors. This unavailability of alternative treatment represents an underserved and potentially significant market that is waiting for exploration.
New analysis from Frost & Sullivan’s ( http://www.lifesciences.frost.com ) United States Market for Ankylosing Spondylitis Pharmacotherapy research finds that the market earned revenues of more than $496.6 million in 2011 and estimates this to reach $986.3 million in 2017.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at email@example.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
AS is a chronic, inflammatory and genetically related disease that, being highly heritable, translates to a market with a stable patient population. Given that awareness is low, many cases go undiagnosed for years, signifying a much larger opportunity than previously estimated.
“Disease education campaigns could effectively boost the number of patients seeking diagnosis and treatment,” said Frost & Sullivan Senior Industry Analyst Deborah Toscano. “There will be a strong market for advanced, affordable, and disease-modifying drugs with improved safety and true clinical benefits.”
Since TNF inhibitors are a well established therapeutic drug class, they are likely to continue to be used as the first line of treatment in the foreseeable future. TNF inhibitors, as a drug class, have laid the groundwork for the next generation of effective disease modifying antirheumatic drugs and biologics with improved safety and efficacy profiles.
Although therapies such as TNF inhibitors are effective in rheumatoid arthritis as well as ankylosing spondylitis, there is still a large market for specialty drugs. There is substantial potential for alternatives for patients with moderate to severe forms of the disease, who do not respond to these medications. While many patients take well to non-steroidal anti-inflammatory drugs (NSAIDs), there is an unmet need for treatment aimed at symptom relief and slowing of disease progression.
The development of these therapies, however, is hindered by several factors, including the incompletely understood pathogenesis of AS. As medical advances continue to unfold the mechanism of this complex disease, more druggable targets will be discovered, leading to prospective new remedies.
“New participants may struggle to gain market share due to low patient awareness,” noted Toscano. “Nevertheless, aggressive marketing efforts that include patient and physician education could improve the uptake of AS drugs.”
The launch of novel therapies and the ensuing promotional campaigns by competitors will revive interest in AS, stoking commercial acceptance and market expansion.
United States Market for Ankylosing Spondylitis Pharmacotherapy is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: United States Market for Rheumatoid Arthritis Pharmacotherapy, United States Rheumatic Diseases Therapeutics Market, United States Market for Psoriatic Arthritis Pharmacotherapy, and U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.